EyePoint Pharmaceuticals and ImprimisRx have signed a commercial alliance regarding promotion of Dexycu in the United States, according to a press release.
ImprimisRx will promote Dexycu (dexamethasone intraocular suspension 9%), approved to treat postoperative inflammation after ocular surgery, to U.S. ophthalmologists, hospitals and ASCs, initially focusing on accounts that are already purchasing Tri-Moxi (triamcinolone acetonide, moxifloxacin HCl). EyePoint’s responsibilities include marketing, selling, pricing, manufacturing and contracting for Dexycu, and it will retain all
Uncategorized